Skip to main content

ACR 2026 RheumNow Lupus Topic Compilation d

Nov 16, 2026 2:50 pm
The InVivo Wave Hype or Hope 5mg kg HCQ Threshold in SLE Is it Time to Reconsider Lessons learned from ReBioLup data in Lupus Nephritis

Transcription

This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.

Go to rheumnow.live to see the full program and register today.

Hi. My name is Al Kim. I'm at, ACR Convergence twenty twenty six in Orlando, Florida. And within this CAR T cell world, we're gonna be talking about in this topic discussion about in vivo CAR T cells. There were several as...

Abstracts here at this conference using in vivo CAR T cell, almost all from China, but they actually are starting to generate data within humans with autoimmune diseases. So let's talk about what they are and what the promise is and what they're actually delivering. So, you know, I think the main thing that CAR T... In vivo CAR T cells allow you to get is an ability to not have to use any lymphodepletion because you are actually infecting your own T cells with a virus that allows them to be CAR T cells. You don't need to get rid of them.

And as a result, especially with autologous, you don't have to wait for a manufacturing slot and wait two, three, five weeks for the cells to come back in order to inject. So there are a couple different types of in vivo CAR T cell CAR T cell strategies right now. One of them uses a lentivirus delivery system and one of them uses what's called a LNP or lipid nanoparticle that usually carries messenger RNA. So with the lentivirus, this virus is going to infect the t cell, but what it does is that it delivers the CAR construct genetic information into the cell's genome and integrates it there. The integration allows for long...

Lifelong expression of the CAR, even in daughter cells because, again, it's integrated in the genome. But at the same time, integration concerns may occur and if it integrates in say a proto oncogene and activates it, it increases your cancer risk. With lipid nanoparticles that have messenger RNA in them, these are designed to be transient. They come in, they float into a t cell, usually targeted by an antibody that allows them to get to the t cell. The t cell then makes the CAR construct, usually very quickly, but then since it's mRNA that's outside of the nucleus and definitely not DNA that allows to...

That integrates into the genome, it's lost. And so usually the CAR T cells just live for a short period of time and the impact goes away. There's a theoretical advantage for that too because you have a a kind of a controllable on switch. You can just try to redose every time you need to, get more CAR T cells and then just wait for the effect to wane off. So let's talk about the two, the three different abstracts here that allows us...

That, were presented that I felt like had the most information. There's one compound called JY two three one. It's a lentiviral based delivery system. And, this, another one is RXIM two. This is a circular RNA lipid nanoparticle.

This is targeting c seven, which is found on activated, which are found on a subset of t cells. And then another one is r n v one zero one, another linear, micro, messenger RNA, but lipid nanoparticle delivery system that's targeting CD eight. So what separates these is gonna be the onset of action. Arnavy was able to get 94% peripheral b cell depletion in the blood within six hours at their lowest dose. RXIM zero zero two, that's his IV delivery.

They got CAR positive b, t cells in, four to six hours that were identified in the bloodstream. J y two three one, because it's lentiviral, it takes a lot more time for it to kick into place. So you weren't able to see any, CAR T cells until about a few days until a few days after and peaking around day ten to day seventeen. So you're looking at hours versus days, lipid nanoparticle versus, lentivirus. The counterintuitive point though, and this is one of the takeaways I want you to go with, is that the depletion certainly outlast the payload.

Arniv one hundred one was able to maintain B cell depletion up to three months in the two patients that they treated. RXIM002, IV was able to reach LLDAS endorsed in patients to month five and transient expression as a result doesn't necessarily mean transient effect. Now two things especially from the RXIM-two that you have to be aware of despite their positive clinical data they had issues in terms of relapse. Half their patients relapsed by month six and also they had several grade three events in five out of six patients including one thrombotic microangiopathy. RNV one zero one was the quietest.

They only had a grade one CRS and no ICANS, but again, they only dosed two patients. So the feasibility, think, is settled. Whether a transient payload reaches the t... Tissue depth that autologous CAR T cells is able to reach remains unknown. And, also, whether redosing substitutes for for depth, that's a trial we need.

Hello, everyone. This is Bella Mehta from RheumNow reporting live from ACR twenty twenty six, and I have with me Shivani Garg, who's an amazing researcher, and we're gonna talk about a study that was one of the most downloaded studies today. It was a poster, but talking about something that I think is very important is what do we do with hydroxychloroquine dosage? So can you tell me what was your study and why do you think it's important and what's the takeaway?

Yeah, great. Thank you for having me. And so we have all our, my clinician colleagues have all been there. You have been there. I've been there.

We have an email from our ophthalmologist saying, Oh, the dose is five milligram, more than five milligram per kilogram for hydroxychloroquine that we use for almost all patients with lupus. So what to do now? Is it safe? Where is this threshold coming from? But there is also evidence and data that has been published recently that having the dose below or at five milligram per kilogram per day is also associated with six fold higher risk of having lupus flare that can put a patient into the hospital.

So you're saying that we are under dosing some patients?

Yes. So it's not clear whether this is the threshold which is safe and effective. So we wanted to have a closer look with more patient data. So what we did was a meta analysis. It's an individual patient data meta analysis.

Pools data from different cohorts including the SLIC, which is an international cohort, Wisconsin cohort, Mastro and Brigham's, and Kaiser Permanente cohort.

And these are all lupus patients?

These are all lupus patients. And they have a minimum exposure of five years to hydroxychloroquine, just because we know that early on it's a cumulative toxicity, we made sure that all patients had at How least five

patients were

there? 2,533.

Okay, so it's around 2,500 So it's a big, large size sample Yeah.

So what we did was that for some data sets such as Mastroian Brigham and Kaiser Permanente, which was with help of my collaborator and co author on this paper, Doctor. April George. So we had log hazards ratio with every zero point zero one milligram per kilogram dose increase. What it means is that we had time to hazards or risk of having toxicity. And then from other cohorts, had Lyme level data.

So we converted it into the same log hazards ratio so that we can pool the data together.

Okay. And what did you conclude? Yeah.

So when we pooled all hazards ratio together, we noted that we did a linear... Non linear... Linearity trend analysis. What it means is that we put a threshold. So now we set the threshold or cutoff at four, five, six, and 6.5, which was the old threshold for hydroxychloroquine safety.

We noted that it's a linear association. There is no clear cutoff when we come to hydroxychloroquine safe dosing.

Okay. Like in everything, right? Instead of having a hard line in the sand, there's like a threshold or a curve.

Yeah. So it was not curve, it was So a straight what it means to our clinician colleagues is that if you dose a patient at five milligrams or maybe six and a half milligrams and dose, they reach to toxicity of four percent risk in twenty years. For people who are dosed at five milligrams, they will reduce the same toxicity in twenty two years. So that's the difference. It's not about that there is a safe threshold that above all toxicity lies above five milligram per kilogram and no toxicity below.

Yeah. It just means that it is the cumulative exposure.

So so all you're saying is that don't go crazy with the five milligram line threshold. If you need to give a little more, you'd rather on the side of that. All it will change is the risk of toxicity decades down.

Exactly.

And you'd rather dose it well than under dose it. Is that what I took away?

Exactly. But personalize it because there are patients who, and we know that lupus patients tend to flare early on. So in the first five years, if it is a difficult to control lupus, they have some flares or residual symptoms, you might want

to increase the The load up front.

Yeah, and the the ACR guidelines allow that to tailor based on the activity of lupus. Yes. And then once they are stable, you can safely or closely monitoring them could bring down the dose to the threshold so that they can take it longer.

Great. So I I think that that's that's something that we need to take away and also educate our ophthalmology colleagues because that's the panic email that you were starting to talk about. Yeah. So I guess, is there something that you are okay with? A threshold that you're probably okay with?

The dose wise. So a lot of times what I do is that I use the threshold as a guide, particularly when my patients are stable. Then I might want to get them down a little towards the threshold so that they can take it longer because the data for hydroxychloroquine, it's not just about controlling lupus, it is about preventing damage and survival. So with that data, want them to take it longer till the time they don't need it. And so that's what I do, but I also add a layer of hydroxychloroquine blood level monitoring.

Okay, yeah. That's another thing that we have to, we as clinicians need to start thinking about and So, this is very helpful and very useful for I think my key takeaway is don't be scared of the five milligram threshold, go hard up front, and your data is very thoroughly well done study showing that. So with that, thank you so much for joining, and thank you for listening. For more, just follow us on RheumNow.

Hello. I'm Sheila Reyes from The Philippines, and I'm here reporting at RheumNow for ACR twenty twenty six in sunny Orlando, Florida. One of the abstracts presented today discussed repeat biopsy data from ReBioLoop. That's abstract number one eight six two. And joining me is the main author, doctor Ioannis Parodis of the Karolinska Institute.

Hello, doctor Parodis, thank you for joining us.

Thank you for inviting me, and thank you for your interest in Rebileup. I have to say that we are many who are doing a study, many who are in the effort. So I'm representing the work of many people.

Yes. And it's truly an important work and that's why we want to really know more about it. So please talk us or talk us through about your methods and then the results that you saw in your study.

Yes, so I can take it a little bit from the beginning. What triggered our interest to design ReBioLock was an apparent discourse between clinical and histological outcomes after treatment for active lupus nephritis. So when you do the repeat kidney biopsy, which we do traditionally in our center and other centers traditionally do a repeat kidney biopsy. What we have observed is that proteinuria at the time of the repeat kidney biopsy and activity index scores on the repeat kidney biopsies, they do not really go together. So there is a moderate correlation between levels of proteinuria and activity index scores, but you still have patients with low levels of proteinuria and still histological activity which is treatable and you miss it if you don't do the repeat kidney biopsy and you also have patients with fixed proteinuria which depends on damage and these patients do not need treatment.

For both treating a patient who needs therapy and you would miss if you don't do the repeat kidney biopsy and for patients that you would over treat if you wouldn't do the repeat kidney biopsy, you need to perform a repeat biopsy. So what we designed years ago was a randomized trial where we randomized the patients one to one patients with active lupus nephritis, incident cases of lupus nephritis, both proliferative and membranous. We randomize a class three or four and pure class five separately. So we randomize the patients to either undergo or not undergo a repeat kidney biopsy at one year. And our hypothesis is that with the information that we glean from the repeat kidney biopsy, we will have changes in therapy that in turn will result in a greater proportion of patients that achieve complete renal response after two years and the greater proportion of patients that preserve their kidney function after five years in the repeat kidney biopsy arm compared with the comparator arm which is no repeat kidney biopsy.

All right. And so what were, I believe these are interim analysis data that you presented earlier. And how did that go about? What were the results of your study?

Yes. We wanted to present interim data in order to inform current discussions regarding end points because it becomes apparent to us that the current end points that we have in trials of lupus nephritis are not optimal. So we took the advantage of REPILOOP. We had at the time of the data cut, we had one hundred and sixty eight patients randomized. Now we have one hundred and eighty five patients randomized and forty seven patients from the repeat kidney biopsy arm had the repeat kidney biopsies performed.

So we had this data, we could do the correlation between proteinuria and activity index scores on the repeat kidney biopsy. We saw a moderate correlation, what you could expect, but we also had some other interesting findings. One that a substantial proportion of patients still had activity index of four or higher, which is a lot, despite modern therapy, BioLoop is a modern study. And a number of patients, substantial number of patients met despite the fact that they met the proteinuria cutoff that we usually see in the clinical trial endpoints, which is zero point five grams per gram or grams per day. And despite that they had a substantial amount of activity in their repeat kidney biopsy, so four or higher.

So that's a lot. And we said, okay, it might be the cutoff that is the problem, the 0.5. So we gave proteinuria a chance and said, which is the cutoff of proteinuria at the time of the repeat kidney biopsy that best predicts what we consider a good outcome, which is an activity index zero on the repeat kidney biopsy. And indeed we found the optimal threshold of proteinuria to be zero point two two grams per gram. But the details are the important things.

If the positive predictive value was moderate, it was forty seven percent and the negative predictive value was excellent, it was ninety seven percent. So what does it tell us? It tells us that if you have not achieved the target, which in this case is proteinuria below 0.22 grams per gram, then your chances to have an activity in X0 on their PK in a biopsy are nearly in existence. And if you have achieved the target, then we cannot really tell what's happening in the kidney. So this makes the repeat kidney biopsy still imperative.

So we need to perform the repeat kidney biopsy in order to know what's happening in the kidney and plan our treatment management. This is the main

message take away

from the study.

So just to go back to that. So with the threshold that you've established, is point two, so if patients are still above that threshold... I mean, the proteinuria threshold is more than point two, this... Even if in the absence or, like, even if there are other in the absence of other factors, our repeat biopsy would still be warranted. Is that what the study is saying?

Unless one could tell us that we would intensify therapy anyway, because the chances to have achieved an activity index zero are very low to inexistent. And then when you reach the threshold of less than 0.22 grams per gram, then you have to do a repeat kidney biopsy in order to see how you should continue with your management, with your therapy. So this is what the data tell

It's showing us.

Yes.

Okay. I believe that's impressive work on your end and with future directions, more patients will be coming in.

Yes. We now have randomized one hundred and eighty five patients and we will complete recruitment when we have reached two zero six patients according to our power calculations of proliferative class three or four lupus nephritis. We also recruit patients with pure membranous lupus nephritis in parallel, but we do not count them towards the completion of recruitment. So whenever we have two zero six patients with class three or four lupus nephritis, then we close recruitment and of course we're eager to see what those data will tell us. In parallel with the clinical questions, we also collect serum, we collect suction tubes, collect urine and we collect kidney tissue in order to also do translational research because of course we're advocates of the repeat kidney biopsy, but in the end of the day what we want to achieve is to find the good substitute of the repeat kidney biopsy.

So repeat kidney biopsy at the moment is important also for research purposes.

Agree. I agree. So very well said. But before we end, I would just like to ask, given all this data, what do you think would be a clinical application, at least a takeaway for our clinicians out there that they can get from your results, from the interim results of the study?

So the most important takeaway I think is that low proteinuria, even if it is very low, does not really tell us the entire story, does not really tell us that we have achieved what we can consider an optimal outcome in patients with lupus nephritis, which is an activity index zero. And actually we also did an analysis of an activity index zero or one, and the results were very similar. So, we need to look into the tissue, at least as long as we do not have optimal biomarkers that can track activity in the kidney.

Okay. Well said. And thank you very much, doctor Ioannis, for joining us today and sharing your time and even the result... Especially the results of this study. K?

And we're looking forward to the additional results of your studies as the... As we go along further along. So thank you very much again.

Thank you for highlighting our study, and I... We are both eager to see what we have what's coming next.

Correct. We're really looking forward to it. Okay. So thank you very much. Again, I'm Sheila Reyes.

Follow me on X at RheumNowRampA, and tune in to RheumNow for more updates of the ACR twenty twenty six.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×